[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?",
    "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days.  On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).  Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain.",
    "url": "https://finnhub.io/api/news?id=815641c24dd1f3505e60b221e94dff3957cb708a4591341e3b7fd7a2cb2db6b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738501560,
      "headline": "Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?",
      "id": 132631709,
      "image": "https://g.foolcdn.com/editorial/images/806025/fda-approved.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days.  On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).  Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain.",
      "url": "https://finnhub.io/api/news?id=815641c24dd1f3505e60b221e94dff3957cb708a4591341e3b7fd7a2cb2db6b3"
    }
  },
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?",
    "summary": "Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street.  Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news.  The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025.",
    "url": "https://finnhub.io/api/news?id=6d3f7b9aac55b69331499d8b947de9f53884fe2ca19282a08965ae294bc92f1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738492500,
      "headline": "Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?",
      "id": 132631710,
      "image": "https://g.foolcdn.com/editorial/images/806019/individual-investor-looking-at-stock-charts-getty.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street.  Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news.  The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025.",
      "url": "https://finnhub.io/api/news?id=6d3f7b9aac55b69331499d8b947de9f53884fe2ca19282a08965ae294bc92f1d"
    }
  }
]